A Phase 1 interventional study of VAY736 and ibrutinib in Chronic Lymphocytic Leukemia (CLL), sponsored by Novartis Pharmaceuticals. Terminated at 5 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis — none open to participants now, 1 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Novartis.
Among the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 1, and was the 11th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →None of the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 3
First in 1998; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is close to the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 39 across the 13 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients enrolled to the study had chronic lymphocytic leukemia (CLL) and received ibrutinib. Patients had either received ibrutinib for one year without having had a complete response or patients developed a resistance mutation to ibrutinib. This study had two parts, a dose escalation part and a dose expansion part.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.
Drug: VAY736 · Drug: ibrutinib
Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.
Drug: VAY736 · Drug: ibrutinib
Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1 (Escalation Only)
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 28 days of treatment with the combination of VAY736 and ibrutinib and meets the criteria defined in the study protocol. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
Time frame: 28 days
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with AEs (any AE regardless of seriousness) and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. All patients were followed for a 30-day safety follow-up period subsequent to completion of VAY736 therapy. No new AEs or SAEs were collected beyond the 30-day safety follow-up or during the efficacy follow up period.
Time frame: From first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months
Number of Participants With Dose Reductions and Dose Interruptions of VAY736
For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.
Time frame: Up to 7.8 months
Number of Participants With Dose Reductions and Dose Interruptions of Ibrutinib
For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.
Time frame: Up to 8.5 months
Dose Intensity of VAY736
Dose intensity of VAY736 was calculated as: Actual Cumulative dose (mg/kg) / (Duration of exposure in weeks/2)
Time frame: Up to 7.8 months
Dose Intensity of Ibrutinib
Dose intensity of ibrutinib was calculated as: Actual Cumulative dose (mg) / (Duration of exposure in days)
Time frame: Up to 8.5 months
CR or CRi Rate at C9 for Expansion Arm A and Arm B by Investigator Per IWCLL
Percentage of participants with Complete Response (CR) or Complete Response with Incomplete Marrow Recovery (CRi) by investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.
Time frame: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.
Posterior Mean of CR or CRi Response Rate at C9 for Expansion Arm A and Arm B (Bayesian Analysis)
The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach. A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%. Values estimated from the model at Cycle 9 are presented in the table. Posterior geometric mean for CR/CRi rate and 90% credible intervals in each group are presented.
Time frame: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.
Posterior Probability That the True CR or CRi Response Rate at C9 for Expansion Arm A and Arm B Falls in Pre-defined Activity Intervals (Bayesian Analysis)
The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach. A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%. Values estimated from the model at Cycle 9 are presented in the table. The posterior probability that the true CR/CRi rate falls in the activity intervals defined below is presented: * \[0, 20%) - clinically not meaningful * \[20%, 40%) - moderate clinical benefit * \[40%, 100%\] - superior clinical benefit
Time frame: Cycle 9 Day 1 (C9). The duration of each cycle was 28 days.
Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Escalation Part
Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).
Time frame: Up to approximately 2.5 years
Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Expansion Part
Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).
Time frame: Up to approximately 2.7 years
Time to Progression (TTP) in the Dose Escalation Part
Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer. If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment. TTP was analyzed using Kaplan-Meier estimates.
Time frame: Up to approximately 2.5 years
Time to Progression (TTP) in the Dose Expansion Part
Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer. If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment. TTP was analyzed using Kaplan-Meier estimates.
Time frame: Up to approximately 2.7 years
Percentage of Participants With Clearance of Ibrutinib Resistance Mutation During Treatment (up to C9) for Expansion Arm B
Clearance was defined as less than 1% mutation bearing alleles (BTKC481 and/or PLCγ2) during treatment. Negative mutation is defined as having clearance of the baseline ibrutinib resistance mutation during treatment (up to Cycle 9 (C9)).
Time frame: Up to Cycle 9 Day 1. The duration of each cycle was 28 days.
Maximum Observed Serum Concentration (Cmax) of VAY736
Pharmacokinetic (PK) parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Time frame: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days
Time to Reach Maximum Serum Concentration (Tmax) of VAY736
PK parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.
Time frame: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days
Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of VAY736
PK parameters were calculated based on VAY7736 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Time frame: Pre-infusion and 2, 6, 24, 72, 168 and 336 hours after end of infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was approximately 2 hours. 1 cycle=28 days
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
Time frame: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days
Time to Reach Maximum Plasma Concentration (Tmax) of Ibrutinib
PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.
Time frame: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Ibrutinib
PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
Time frame: Pre-dose and 0.5, 2, 6 and 24 hours post-dose on Cycle 1 Day 1 and Cycle 1 Day 8. 1 cycle=28 days
Number of Participants With Anti-VAY736 Antibodies
VAY736 immunogenicity was evaluated in serum samples. Anti-drug antibodies (ADA) status was defined as follows: * ADA-negative at baseline: baseline sample where assay is ADA negative * ADA-positive at baseline: baseline sample where assay is ADA positive * ADA-negative post-baseline: ADA-negative sample at baseline and at least 1 post-baseline sample, all of which are ADA-negative samples * Treatment-induced ADA-positive: ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample * Treatment-boosted ADA-positive: ADA-positive sample at baseline and at least 1 treatment-boosted ADA-positive sample * ADA-inconclusive post-baseline: patient who does not qualify for any of the above definitions
Time frame: Baseline (before first dose) and post-baseline (assessed throughout the VAY736 treatment, up to 7.8 months).
A total of 39 patients were enrolled in the study. Fifteen patients participated in the dose escalation part across four treatment arms: VAY736 0.3 mg/kg Q2W + ibrutinib 420 mg, VAY736 1 mg/kg Q2W + ibrutinib 420 mg, VAY736 3 mg/kg Q2W + ibrutinib 420 mg, and VAY735 9 mg/kg + ibrutinib 420 mg. The remaining 24 subjects were enrolled in the expansion part and were treated with VAY736 3 mg/kg Q2W in combination with ibrutinib 420 mg or 280 mg.
| Milestone | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Started | 4 | 3 | 0 | 4 | 4 |
| Completed | 3 | 2 | 0 | 4 | 2 |
| Not completed | 1 | 1 | 0 | 0 | 2 |
| Withdrew: Progressive disease | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Patient decision | 0 | 0 | 0 | 0 | 1 |
| Milestone | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 1 | 23 | 0 |
| Group a | 0 | 0 | 0 | 19 | 0 |
| Group b | 0 | 0 | 1 | 4 | 0 |
| Completed | 0 | 0 | 0 | 19 | 0 |
| Not completed | 0 | 0 | 1 | 4 | 0 |
| Withdrew: Patient decision | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 1 | 0 |
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications that occurs within the first 28 days of treatment with the combination of VAY736 and ibrutinib and meets the criteria defined in the study protocol. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
| Participants | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1 (Escalation Only) | 0 | 0 | 0 | 0 |
Number of participants with AEs (any AE regardless of seriousness) and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. All patients were followed for a 30-day safety follow-up period subsequent to completion of VAY736 therapy. No new AEs or SAEs were collected beyond the 30-day safety follow-up or during the efficacy follow up period.
| Participants | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| AEs | 4 | 3 | 1 | 27 | 4 |
| Treatment-related AEs | 2 | 2 | 1 | 15 | 1 |
| AEs with grade >=3 | 1 | 2 | 1 | 12 | 0 |
| Treatment-related AEs with grade >=3 | 0 | 1 | 1 | 7 | 0 |
| SAEs | 0 | 1 | 0 | 1 | 0 |
| Treatment-related SAEs | 0 | 1 | 0 | 1 | 0 |
| Fatal SAEs | 0 | 0 | 0 | 0 | 0 |
For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.
| Participants | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| At least one dose reduction or interruption | 0 | 1 | 0 | 5 | 0 |
| At least one dose reduction | 0 | 0 | 0 | 1 | 0 |
| At least one dose interruption | 0 | 1 | 0 | 5 | 0 |
For patients who did not tolerate the protocol-specified dosing schedule of the study drugs, dose adjustments could be permitted in order to allow the patient to continue study treatment.
| Participants | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| At least one dose reduction or interruption | 0 | 1 | 0 | 10 | 0 |
| At least one dose reduction | 0 | 0 | 0 | 0 | 0 |
| At least one dose interruption | 0 | 1 | 0 | 10 | 0 |
Dose intensity of VAY736 was calculated as: Actual Cumulative dose (mg/kg) / (Duration of exposure in weeks/2)
| mg/kg/2 weeks | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Dose Intensity of VAY736 | 0.30 (0.3 to 0.3) | 0.98 (0.9 to 1.0) | 3.00 (3.0 to 3.0) | 3.00 (1.4 to 3.0) | 8.97 (8.9 to 9.0) |
Dose intensity of ibrutinib was calculated as: Actual Cumulative dose (mg) / (Duration of exposure in days)
| mg/day | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Dose Intensity of Ibrutinib | 420.00 (420.0 to 420.0) | 420.00 (407.7 to 420.0) | 280.00 (280.0 to 280.0) | 420.00 (395.7 to 420.0) | 420.00 (420.0 to 420.0) |
Percentage of participants with Complete Response (CR) or Complete Response with Incomplete Marrow Recovery (CRi) by investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria.
| percentage of participants | VAY736 3mg/kg Q2W Arm A + Ibrutinib 420mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 280mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 420mg | All Patients Expansion |
|---|---|---|---|---|
| CR or CRi Rate at C9 for Expansion Arm A and Arm B by Investigator Per IWCLL | 47.4 (27.4 to 68.0) | 0 (0 to 95.0) | 0 (0 to 52.7) | 37.5 (21.2 to 56.3) |
The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach. A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%. Values estimated from the model at Cycle 9 are presented in the table. Posterior geometric mean for CR/CRi rate and 90% credible intervals in each group are presented.
| percentage of participants | VAY736 3mg/kg Q2W Arm A + Ibrutinib 420mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 280mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 420mg | All Patients Expansion |
|---|---|---|---|---|
| Posterior Mean of CR or CRi Response Rate at C9 for Expansion Arm A and Arm B (Bayesian Analysis) | 45.68 (28.1 to 63.7) | 11.11 (0 to 51.6) | 4.76 (0 to 23) | 36.63 (21.8 to 52.7) |
The rate of CR/CRi at C9 was analyzed for each expansion arm using a Bayesian modeling approach. A minimally informative beta distribution was used as prior distribution with parameters a=0.25 and b=1. This assumed, a priori, that the response rate was 20%. Values estimated from the model at Cycle 9 are presented in the table. The posterior probability that the true CR/CRi rate falls in the activity intervals defined below is presented: * \[0, 20%) - clinically not meaningful * \[20%, 40%) - moderate clinical benefit * \[40%, 100%\] - superior clinical benefit
| percentage of participants | VAY736 3mg/kg Q2W Arm A + Ibrutinib 420mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 280mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 420mg | All Patients Expansion |
|---|---|---|---|---|
| [0, 20%) - clinically not meaningful | 0.5 | 80.2 | 93.6 | 3 |
| [20%, 40%) - moderate clinical benefit | 30.4 | 11.3 | 5.3 | 61.8 |
| 40%, 100%] - superior clinical benefit | 69.1 | 8.5 | 1.1 | 35.2 |
Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).
| percentage of participants | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg | All Patients Escalation |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Escalation Part | 50.0 (9.8 to 90.2) | 0 (0 to 63.2) | 50.0 (9.8 to 90.2) | 50.0 (9.8 to 90.2) | 40.0 (19.1 to 64.0) |
Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. ORR per IWCLL is defined as the percentage of participants with a best overall response of Complete Response (CR), Complete Response with Incomplete Marrow Recovery (CRi) or Partial Response (PR).
| percentage of participants | VAY736 3mg/kg Q2W Arm A + Ibrutinib 420mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 280mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 420mg | All Patients Expansion |
|---|---|---|---|---|
| Overall Response Rate (ORR) Assessed by Investigator Per IWCLL in the Dose Expansion Part | 84.2 (64.1 to 95.6) | 0 (0 to 95.0) | 25.0 (1.3 to 75.1) | 70.8 (52.1 to 85.4) |
Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer. If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment. TTP was analyzed using Kaplan-Meier estimates.
| months | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg | All Patients Escalation |
|---|---|---|---|---|---|
| Time to Progression (TTP) in the Dose Escalation Part | 23.3 (2.8 to NA) | 8.3 (1.8 to NA) | 24.2 (5.6 to NA) | 19.4 (2.8 to NA) | 19.4 (2.8 to 25.1) |
Efficacy was based on local investigator assessment per International Working Group - Chronic Lymphocytic Leukemia (IWCLL) response criteria. TTP is defined as the time from start of treatment to date of event which is defined as the first documented progression or death due to underlying cancer. If a patient had not had an event, TTP was censored at the date of the last adequate disease assessment. TTP was analyzed using Kaplan-Meier estimates.
| months | VAY736 3mg/kg Q2W Arm A + Ibrutinib 420mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 280mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 420mg | All Patients Expansion |
|---|---|---|---|---|
| Time to Progression (TTP) in the Dose Expansion Part | NA (26.3 to NA) | 2.3 (NA to NA) | NA (NA to NA) | NA (26.3 to NA) |
Clearance was defined as less than 1% mutation bearing alleles (BTKC481 and/or PLCγ2) during treatment. Negative mutation is defined as having clearance of the baseline ibrutinib resistance mutation during treatment (up to Cycle 9 (C9)).
| percentage of participants | VAY736 3mg/kg Q2W Arm B + Ibrutinib 280mg | VAY736 3mg/kg Q2W Arm B + Ibrutinib 420mg | All Patients Expansion Arm B |
|---|---|---|---|
| Percentage of Participants With Clearance of Ibrutinib Resistance Mutation During Treatment (up to C9) for Expansion Arm B | 0 (0 to 95.0) | 0 (0 to 52.7) | 0 (0 to 45.1) |
Pharmacokinetic (PK) parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
| µg/mL | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Cycle 1 | 9.61 ± 23.0 | 15.8 ± 59.8 | 65.9 | 59.4 ± 15.8 | 178 ± 26.7 |
| Cycle 3 | 11.2 ± 21.2 | 21.6 ± 38.8 | — | 72.5 ± 33.9 | 260 ± 13.3 |
PK parameters were calculated based on VAY736 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.
| hours | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Cycle 1 | 4.30 (2.40 to 6.00) | 3.90 (2.00 to 5.80) | 2.20 (2.20 to 2.20) | 4.70 (2.00 to 6.10) | 5.80 (2.20 to 6.00) |
| Cycle 3 | 2.00 (2.00 to 2.10) | 2.20 (2.10 to 2.30) | — | 2.10 (2.00 to 22.70) | 2.15 (0.00 to 2.70) |
PK parameters were calculated based on VAY7736 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
| hr*µg/mL | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Cycle 1 | 46.0 ± 29.1 | 55.5 ± 46.0 | 217 | 256 ± 19.1 | 930 ± 25.0 |
| Cycle 3 | 75.6 ± 31.7 | 166 ± 48.2 | — | 368 ± 55.2 | 1780 ± 18.1 |
PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.
| ng/mL | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 93.5 ± 120.6 | 123 ± 28.8 | 212 | 83.3 ± 146.9 | 104 ± 62.7 |
| Cycle 1 Day 8 | 94.9 ± 84.4 | 158 ± 53.0 | — | 62.2 ± 149.4 | 97.0 ± 54.1 |
PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) concentration following a dose. Actual recorded sampling times were considered for the calculations.
| hours | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.10 (1.90 to 2.10) | 2.00 (2.00 to 2.10) | 2.30 (2.30 to 2.30) | 2.10 (0.60 to 6.80) | 2.00 (1.90 to 2.20) |
| Cycle 1 Day 8 | 2.00 (1.50 to 6.00) | 2.00 (1.90 to 2.10) | — | 2.00 (0.50 to 2.50) | 2.00 (1.90 to 2.00) |
PK parameters were calculated based on ibrutinib plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation.
| hr*ng/mL | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 541 ± 145.3 | 938 ± 63.4 | 890 | 696 ± 98.5 | 634 ± 34.6 |
| Cycle 1 Day 8 | 338 ± 69.6 | 552 ± 41.8 | — | 226 ± 134.0 | 323 ± 54.7 |
VAY736 immunogenicity was evaluated in serum samples. Anti-drug antibodies (ADA) status was defined as follows: * ADA-negative at baseline: baseline sample where assay is ADA negative * ADA-positive at baseline: baseline sample where assay is ADA positive * ADA-negative post-baseline: ADA-negative sample at baseline and at least 1 post-baseline sample, all of which are ADA-negative samples * Treatment-induced ADA-positive: ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample * Treatment-boosted ADA-positive: ADA-positive sample at baseline and at least 1 treatment-boosted ADA-positive sample * ADA-inconclusive post-baseline: patient who does not qualify for any of the above definitions
| participants | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| ADA-negative at baseline | 4 | 3 | 1 | 24 | 4 |
| ADA-positive at baseline | 0 | 0 | 0 | 3 | 0 |
| ADA-negative post-baseline | 4 | 3 | 1 | 24 | 4 |
| ADA-inconclusive post-baseline | 0 | 0 | 0 | 0 | 0 |
| Treatment-induced ADA-positive | 0 | 0 | 0 | 0 | 0 |
| Treatment-boosted ADA-positive | 0 | 0 | 0 | 0 | 0 |
On-treatment deaths were collected from first dose of study treatment to 30 days after the last dose of VAY736. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study. All deaths refer to the sum of on-treatment and post-treatment deaths.
| participants | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg |
|---|---|---|---|---|---|
| On-treatment deaths | 0 | 0 | 0 | 0 | 0 |
| Post-treatment deaths | 0 | 0 | 0 | 1 | 0 |
| All deaths | 0 | 0 | 0 | 1 | 0 |
Collected over Adverse events (AEs) were collected on-treatment, from first dose of study treatment up to 30 days after the last dose of VAY736, up to approximately 8.8 months. No AEs were collected in the post-treatment period. Deaths were collected on-treatment, from first dose of study treatment to 30 days after the last dose of VAY736, up to approximately 8.8 months. Post-treatment deaths were collected from 31 days after last dose of VAY736 until end of study, up to approximately 2.7 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| VAY736 1mg/kg Q2W + Ibrutinib 420mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| VAY736 3mg/kg Q2W + Ibrutinib 280mg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| VAY736 3mg/kg Q2W + Ibrutinib 420mg | 0/27 (0%) | 2/27 (7.4%) | 27/27 (100%) |
| VAY736 9mg/kg Q2W + Ibrutinib 420mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| All patients_On-treatment | 0/39 (0%) | 4/39 (10.3%) | 39/39 (100%) |
| VAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatment | 0/4 (0%) | — | — |
| VAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatment | 0/3 (0%) | — | — |
| VAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatment | 0/1 (0%) | — | — |
| VAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatment | 1/27 (3.7%) | — | — |
| VAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment | 0/4 (0%) | — | — |
| Event | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg | All patients_On-treatment | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatment | VAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatment | VAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatment | VAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatment | VAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Escherichia sepsisInfections and infestations | 0/4 | 1/3 | 0/1 | 0/27 | 0/4 | 1/39 | — | — | — | — | — |
| Neutrophil count decreasedInvestigations | 0/4 | 1/3 | 0/1 | 1/27 | 0/4 | 2/39 | — | — | — | — | — |
| Small intestinal obstructionGastrointestinal disorders | 0/4 | 0/3 | 0/1 | 1/27 | 0/4 | 1/39 | — | — | — | — | — |
| Non-cardiac chest painGeneral disorders | 0/4 | 0/3 | 0/1 | 1/27 | 0/4 | 1/39 | — | — | — | — | — |
| Event | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg | All patients_On-treatment | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg_Post-treatment | VAY736 1mg/kg Q2W + Ibrutinib 420mg_Post-treatment | VAY736 3mg/kg Q2W + Ibrutinib 280mg_Post-treatment | VAY736 3mg/kg Q2W + Ibrutinib 420mg_Post-treatment | VAY736 9mg/kg Q2W + Ibrutinib 420mg_Post-treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/4 | 3/3 | 0/1 | 8/27 | 1/4 | 14/39 | — | — | — | — | — |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 1/1 | 0/27 | 0/4 | 1/39 | — | — | — | — | — |
| DiarrhoeaGastrointestinal disorders | 0/4 | 3/3 | 0/1 | 2/27 | 2/4 | 7/39 | — | — | — | — | — |
| Neutrophil count decreasedInvestigations | 1/4 | 3/3 | 0/1 | 4/27 | 1/4 | 9/39 | — | — | — | — | — |
| HyperglycaemiaMetabolism and nutrition disorders | 2/4 | 3/3 | 0/1 | 10/27 | 1/4 | 16/39 | — | — | — | — | — |
| VomitingGastrointestinal disorders | 0/4 | 2/3 | 0/1 | 2/27 | 0/4 | 4/39 | — | — | — | — | — |
| ChillsGeneral disorders | 0/4 | 2/3 | 0/1 | 1/27 | 0/4 | 3/39 | — | — | — | — | — |
| PyrexiaGeneral disorders | 0/4 | 2/3 | 0/1 | 0/27 | 0/4 | 2/39 | — | — | — | — | — |
| Platelet count decreasedInvestigations | 1/4 | 2/3 | 0/1 | 2/27 | 0/4 | 5/39 | — | — | — | — | — |
| White blood cell count decreasedInvestigations | 1/4 | 2/3 | 0/1 | 2/27 | 0/4 | 5/39 | — | — | — | — | — |
Full Analysis Set: All patients who received at least one dose of study treatment in the dose escalation or dose expansion part of the study. Patients were analyzed according to the study treatment received.
| Age, Continuous(years) | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg | Total |
|---|---|---|---|---|---|---|
| Mean | 69.3 ± 6.02 | 61.0 ± 1.73 | 57.0 | 63.5 ± 10.36 | 65.0 ± 10.42 | 63.9 ± 9.50 |
| Age, Customized(Participants) | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg | Total |
|---|---|---|---|---|---|---|
| 18 - < 65 years | 1 | 3 | 1 | 12 | 2 | 19 |
| 65 - < 85 years | 3 | 0 | 0 | 15 | 2 | 20 |
| Sex: Female, Male(Participants) | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 1 | 0 | 7 | 3 | 11 |
| Male | 4 | 2 | 1 | 20 | 1 | 28 |
| Race/Ethnicity, Customized(Participants) | VAY736 0.3mg/kg Q2W + Ibrutinib 420mg | VAY736 1mg/kg Q2W + Ibrutinib 420mg | VAY736 3mg/kg Q2W + Ibrutinib 280mg | VAY736 3mg/kg Q2W + Ibrutinib 420mg | VAY736 9mg/kg Q2W + Ibrutinib 420mg | Total |
|---|---|---|---|---|---|---|
| White | 4 | 2 | 1 | 26 | 3 | 36 |
| Black or African American | 0 | 1 | 0 | 0 | 1 | 2 |
| Missing | 0 | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Sep 2023, 65 months.
Results were first posted in May 2025, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ianalumab
Leukemia, Lymphocytic, Chronic, B-Cell →